新型脂肪因子阿朴脂蛋白血清水平在肢端肥大症患者中显著降低。
Serum Levels of Asprosin, a Novel Adipokine, Are Significantly Lowered in Patients with Acromegaly.
作者信息
Ke Xiaoan, Duan Lian, Gong Fengying, Zhang Yuelun, Deng Kan, Yao Yong, Wang Linjie, Pan Hui, Zhu Huijuan
机构信息
Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.
Central Research Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.
出版信息
Int J Endocrinol. 2020 Dec 14;2020:8855996. doi: 10.1155/2020/8855996. eCollection 2020.
BACKGROUND
Asprosin is a novel identified adipokine secreted mainly by white adipose tissue, which is elevated in metabolic diseases such as diabetes and obesity. Acromegaly is a syndrome caused by pituitary growth hormone (GH) cell adenoma with excessive GH secretion. Serum adipocytokines levels may be involved in abnormal glycolipid metabolism in acromegaly patients.
OBJECTIVES
To investigate serum asprosin levels in acromegaly patients and its correlation with high GH levels and glucolipid metabolic parameters.
METHODS
A retrospective case-control study was conducted and 68 acromegaly patients and 121 controls were included in this study. Clinical information and laboratory examinations were collected and serum asprosin levels were measured by commercial ELISA kits.
RESULTS
Serum asprosin levels in acromegaly patients were significantly lower than controls ( < 0.001). Serum asprosin levels in patients with the course of acromegaly ≥5 years (compared with <5 years), high area under curve of growth hormone (GH-AUC) after 75 g oral glucose tolerance test (OGTT) (compared with low GH-AUC patients), and high IGF-1 SDS group (compared with low IGF-1 SDS group) were significantly reduced (all < 0.05). Serum asprosin levels in acromegaly patients were negatively correlated with the course of acromegaly, IGF-1 SDS, nadir growth hormone value (GH-Nadir), and GH-AUC after OGTT. Multiple stepwise linear regression indicated that acromegaly was an independent influencing factor of serum asprosin levels. According to serum asprosin levels tertiles, the risk of acromegaly in the lowest group was 2.67 times higher than the highest group (OR ＝ 3.665, 95% CI 1.677 ∼ 8.007, =0.001), and the increased risk of the lowest group still existed after adjusting for gender, age, BMI, and TC (Model 2).
CONCLUSIONS
Serum asprosin levels in acromegaly patients are lowered, which may be related to increased blood glucose and reduced body fat mass caused by long-term high GH levels exposure.
背景
阿朴脂蛋白是一种新发现的主要由白色脂肪组织分泌的脂肪因子，在糖尿病和肥胖等代谢性疾病中水平升高。肢端肥大症是一种由垂体生长激素（GH）细胞腺瘤导致GH分泌过多引起的综合征。血清脂肪细胞因子水平可能参与肢端肥大症患者异常的糖脂代谢。
目的
研究肢端肥大症患者血清阿朴脂蛋白水平及其与高GH水平和糖脂代谢参数的相关性。
方法
进行一项回顾性病例对照研究，本研究纳入68例肢端肥大症患者和121例对照。收集临床信息和实验室检查结果，采用商用ELISA试剂盒检测血清阿朴脂蛋白水平。
结果
肢端肥大症患者血清阿朴脂蛋白水平显著低于对照组（<0.001）。肢端肥大症病程≥5年的患者（与病程<5年相比）、口服75 g葡萄糖耐量试验（OGTT）后生长激素曲线下面积高（GH-AUC）的患者（与GH-AUC低的患者相比）以及胰岛素样生长因子-1标准差积分（IGF-1 SDS）高的组（与IGF-1 SDS低的组相比）血清阿朴脂蛋白水平均显著降低（均<0.05）。肢端肥大症患者血清阿朴脂蛋白水平与肢端肥大症病程、IGF-1 SDS、生长激素最低值（GH-Nadir）以及OGTT后GH-AUC呈负相关。多元逐步线性回归表明肢端肥大症是血清阿朴脂蛋白水平的独立影响因素。根据血清阿朴脂蛋白水平三分位数，最低组患肢端肥大症的风险比最高组高2.67倍（OR＝3.665，95%CI 1.677～8.007，=0.001），在调整性别、年龄、BMI和总胆固醇（TC）后，最低组的风险增加仍然存在（模型2）。
结论
肢端肥大症患者血清阿朴脂蛋白水平降低，这可能与长期暴露于高GH水平导致血糖升高和体脂减少有关。
Zotero 插件